Pulling SEC filings + quote and writing the call…

Black Diamond Therapeutics, Inc.
Next earnings Aug 5, 2026 · consensus $-0.20 EPS
Last earnings -3.5% on 2026-05-07
Strong net margin (32.0%).
Quality fundamentals and an attractive price line up (~820% below fair value) — the rarer case where both the business and the entry look good.
Sources: SEC EDGAR (CIK 0001701541, latest 10-Q filed 2026-05-07) · EODHD · as of 6/24/2026, 12:28:40 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Black Diamond Therapeutics, Inc. shows $70.0M in FY2025 revenue, a 32.0% net margin, and 19.9% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $70.0M |
| Gross profit | — | — | — | — | — |
| Operating income | -$127M | -$92.8M | -$86.5M | -$78.8M | $12.5M |
| Net income | -$126M | -$91.2M | -$82.4M | -$69.7M | $22.4M |
| Diluted EPS | -$3.47 | -$2.52 | -$1.88 | -$1.27 | $0.39 |
| Net margin | — | — | — | — | 32.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1483 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
| 2026-06-19 | Behbahani Ali Director | Award | 8.96K @ $1.66 | $14.9K |
| 2026-06-19 | Raman Prakash Director | Award | 7.91K @ $1.66 | $13.1K |
| 2026-03-20 | Behbahani Ali Director | Award | 6.92K @ $2.15 | $14.9K |
| 2026-03-20 | Raman Prakash Director | Award | 6.11K @ $2.15 | $13.1K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.